B Cell News and Research

RSS

SARS-CoV-2 mutations change proteasome processing to alter CD8+ T cell responses

Researchers identified mutations in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoproteins (NP) epitope flanking regions and their potential effects on CD8+ T cell activation.

12 Apr 2022

Unique heightened aggregation of SARS-CoV-2 Delta variant spike pseudotyped particles

A recent study illustrated the enhanced distinct clustering of pseudotyped particles (PPs) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant.

12 Apr 2022

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

In a recent study researchers evaluated the T cell responses elicited by full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein vaccine NVX-CoV2373.

12 Apr 2022

Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

A recent article posted to the bioRxiv* preprint server illustrated that the activation of the Hippo signaling pathway upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection aids the host antiviral response.

11 Apr 2022

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Scientists from the University of Sheffield have discovered a drug already used to treat lung cancer could help to improve survival rates for bladder cancer patients.

11 Apr 2022

Therapies for LGL leukemia should target the immune system, not only cancer cells

An international study coordinated by a University of Helsinki research group demonstrates that the body's immune system attacks itself in a rare type of blood cancer.

11 Apr 2022

Study identifies several therapeutically effective drugs for bladder cancer

Hundreds of chemical compounds were screened on cell cultures representing different stages and subtypes of bladder cancer and several promising agents with inhibitory (growth-inhibiting) effects were identified.

11 Apr 2022

Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

Researchers used cryogenic electron microscopy (cryo-EM) to determine the structure of the spike (S) protein of BA.2 sub-variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) and compared them with previously determined S structures of Omicron's BA.1 sub-variant.

11 Apr 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers - ATR inhibitor elimusertib and PARP inhibitor AZD5305 - are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

Study finds molecular features responsible for the development of metastatic breast cancer

Susana Garcia-Recio, PhD, a research associate in the lab of Charles M. Perou, PhD, at UNC Lineberger Comprehensive Cancer Center, will present findings that identified molecular features responsible for the development and progression of metastatic breast cancer at the 2022 American Association for Cancer Research annual meeting. (Presentation: Abstract LB176/4, Tuesday, April 12, 3:20 p.m. ET, Room 217-219, Ernest N. Morial Convention Center in New Orleans.)

11 Apr 2022

Discovery of key regulator of body weight could lead to new treatments for metabolic disorders

Yale scientists uncover key regulator of body weight. Yale scientists have discovered that a protein known as augmentor-alpha regulates body weight in mice, an insight that could lead to new treatments for metabolic disorders.

11 Apr 2022

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination.

11 Apr 2022

Novel strategy can shrink tumors and prolong survival in mice

A research team based at the University of Ottawa and The Ottawa Hospital has developed a virus that infects and kills cancer cells without harming normal cells, while also sending out signals to prepare nearby uninfected cancer cells for viral attack.

11 Apr 2022

Evidence of an increased risk of neurodegeneration after SARS-CoV-2 infection

...

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Nanocell COVID-19 vaccine elicits potent neutralizing response

A new study describes the high level of neutralizing antibodies elicited by a nanocell vaccine against SARS-CoV-2 in vitro, in vivo, and human studies.

11 Apr 2022

Chromatin accessibility as an early marker of severe COVID-19

A new study explores the possible use of chromatin remodeling in predicting a severe clinical trajectory for COVID-19.

11 Apr 2022

Researchers make progress to develop a drug for treating metabolic syndrome

Metabolic syndrome increases a person's risk for diabetes, heart disease, and stroke, and includes conditions such as obesity, high blood pressure and high blood sugar.

11 Apr 2022

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma.

11 Apr 2022

Study identifies a novel class of angiotensin receptor blockers that interfere with SARS-CoV-2 spike – ACE2 interaction

Scientists have discovered a new generation of angiotensin receptor blockers that may be used to treat coronavirus disease 2019.

11 Apr 2022

B Cell News and Research

SARS-CoV-2 mutations change proteasome processing to alter CD8+ T cell responses

Unique heightened aggregation of SARS-CoV-2 Delta variant spike pseudotyped particles

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Therapies for LGL leukemia should target the immune system, not only cancer cells

Study identifies several therapeutically effective drugs for bladder cancer

Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Study finds molecular features responsible for the development of metastatic breast cancer

Discovery of key regulator of body weight could lead to new treatments for metabolic disorders

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

Novel strategy can shrink tumors and prolong survival in mice

Evidence of an increased risk of neurodegeneration after SARS-CoV-2 infection

New study reveals oral opaganib's potent in vitro activity against Omicron

Nanocell COVID-19 vaccine elicits potent neutralizing response

Chromatin accessibility as an early marker of severe COVID-19

Researchers make progress to develop a drug for treating metabolic syndrome

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Study identifies a novel class of angiotensin receptor blockers that interfere with SARS-CoV-2 spike – ACE2 interaction

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News